In a procedurally significant move at the Court of Appeals for the Federal Circuit, QXMedical, LLC’s cross-appeal against Vascular Solutions, LLC — along with co-defendants Arrow International, LLC, Teleflex Life Sciences, LLC, and Teleflex, LLC — was voluntarily dismissed just 26 days after filing. Case No. 24-1573, resolved on April 10, 2024, centers on a portfolio of reissued and utility patents covering coaxial guide catheters used in interventional cardiology procedures.

While voluntary dismissals may appear routine, this resolution carries meaningful implications for patent practitioners and IP professionals navigating medical device patent litigation. The swift closure of the cross-appeal — while the companion appeal (No. 2024-1572) remains active — signals a deliberate litigation strategy that patent attorneys and R&D teams in the cardiovascular device space should closely monitor. The patents at issue span a portfolio of reissue patents and original utility patents, underscoring the continued relevance of reissue prosecution as a defensive and offensive IP tool.

Case Overview

The Parties

The Patents at Issue

The litigation involves six patents covering coaxial guide catheters used in interventional cardiology procedures. The four reissue patents (USRE045380E, USRE045760E, USRE045776E, USRE046116E) are particularly noteworthy, allowing patentees to correct errors or adjust claim scope under 35 U.S.C. § 251.

• • USRE045380E (Reissue) — Coaxial guide catheter technology
• • USRE045760E (Reissue) — Coaxial guide catheter technology
• • USRE045776E (Reissue) — Coaxial guide catheter technology
• • USRE046116E (Reissue) — Coaxial guide catheter technology
• • US8048032B2 (Utility) — Coaxial guide catheter technology
• • US8142413B2 (Utility) — Coaxial guide catheter technology

Litigation Timeline & Procedural History

The appeal was filed at the Court of Appeals for the Federal Circuit — the exclusive appellate forum for U.S. patent matters — indicating this case originated from district court patent infringement proceedings before reaching the appellate stage.

The 26-day lifespan of Case No. 24-1573 is remarkably short for Federal Circuit proceedings, strongly suggesting that the parties had pre-negotiated the dismissal terms or reached a strategic agreement concurrent with filing. Notably, the court ordered each side to bear its own costs, a standard term in jointly stipulated dismissals under **Federal Rule of Appellate Procedure 42(b)**.

The companion appeal, **No. 2024-1572**, remains active with an opening brief deadline of May 14, 2024, indicating that substantive patent issues remain unresolved between the parties.

The Verdict & Legal Analysis

Outcome

The Federal Circuit dismissed Appeal No. 24-1573 pursuant to a joint stipulation of voluntary dismissal under FRAP 42(b). No damages were awarded in this proceeding, nor was injunctive relief addressed. Each party bears its own appellate costs. Critically, this dismissal does not resolve the underlying patent infringement dispute — that litigation continues under companion Appeal No. 2024-1572.

Verdict Cause Analysis

The stated verdict cause is an infringement action, confirming the underlying dispute involves allegations that Teleflex’s coaxial guide catheter products infringe QXMedical’s patent portfolio. The voluntary dismissal of the cross-appeal specifically — rather than the primary appeal — is the procedurally significant detail here.

A cross-appeal is typically filed when the appellee also seeks modification of the lower court’s judgment (e.g., challenging a claim construction ruling, invalidity finding, or damages calculation that partially disfavored them). Voluntarily dismissing a cross-appeal while maintaining the primary appeal (No. 2024-1572) suggests QXMedical either: (1) achieved a concession or agreement that rendered the cross-appeal moot; (2) made a strategic decision to simplify the appellate record; or (3) reached a partial settlement on specific issues addressed by the cross-appeal. The absence of a disclosed settlement amount or specific basis of termination beyond “voluntary dismissal” limits deeper substantive analysis — a common characteristic of confidential IP settlements.

Legal Significance

Reissue Patent Portfolio Strategy: The presence of four reissue patents (USRE045380E, USRE045760E, USRE045776E, USRE046116E) is strategically meaningful. Reissue patents allow patentees to adjust claim scope after issuance — potentially broadening claims to capture products not anticipated during original prosecution. For Teleflex, defending against a reissue patent portfolio requires careful prosecution history estoppel analysis and recapture rule arguments.

FRAP 42(b) Dismissals: While procedurally unremarkable, joint stipulated dismissals at the Federal Circuit often reflect underlying licensing negotiations, claim narrowing agreements, or strategic repositioning — not necessarily case weakness.

Companion Appeal Watch: The revised caption for Appeal No. 2024-1572 and the May 14, 2024 brief deadline make that proceeding the substantive battleground. Patent practitioners should monitor that docket for claim construction rulings and validity determinations that could set precedent for catheter-based cardiovascular device patents.

Strategic Takeaways

For Patent Holders: Maintaining parallel appeals while selectively dismissing cross-appeals can be a powerful settlement negotiation tool — conceding procedural ground while preserving substantive appellate rights.

For Accused Infringers: When facing reissue patent portfolios, prioritize prosecution history analysis. Reissue proceedings create unique estoppel considerations that can limit infringement claim scope under the doctrine of equivalents.

For R&D Teams: Freedom-to-operate (FTO) analyses involving reissue patents must account for broadened claim language that may not appear in the originally issued patent. Standard FTO clearance on original patents is insufficient when reissue applications are pending or granted.

Industry & Competitive Implications

The interventional cardiology device market is intensely competitive, with guide catheter technologies representing fundamental tools in PCI procedures performed millions of times annually worldwide. Patent exclusivity over coaxial catheter designs — which enable precise navigation of complex coronary anatomy — carries significant commercial value.

For the Teleflex corporate family, this litigation represents a defense of core product lines. Teleflex’s acquisition of Vascular Solutions in 2017 brought with it both valuable catheter technologies and associated IP exposure. The continuation of Appeal No. 2024-1572 means this IP risk remains unresolved on Teleflex’s balance sheet.

For QXMedical, the active appeal represents an ongoing assertion strategy targeting a market-leading competitor. A favorable appellate ruling on claim construction or validity could position QXMedical for substantial licensing revenue or injunctive relief affecting Teleflex’s interventional cardiology product offerings.

More broadly, this case reflects a trend of reissue patent assertion in the medical device space — where smaller patent-holding entities leverage reissued claims against established manufacturers. Companies across the cardiovascular, electrophysiology, and interventional radiology sectors should audit their product lines against active reissue patent portfolios.